Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-06-14Clinical Trial Update: Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia [NA]
This clinical trial update notes the completion of a cell therapy study targeting CD7-positive acute myeloid leukemia or mixed lineage leuke…
-
CLINICAL_TRIALS trial_result · 2024-06-12Clinical Trial Update: Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS [Phase 1]
Phase I clinical trial update from Arcellx evaluating cell therapies for relapsed or refractory acute myeloid leukemia and high-risk myelody…
-
CLINICAL_TRIALS trial_result · 2024-06-11Clinical Trial Update: Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement [Phase 1, Phase 2]
This clinical trial update reports results from a Phase 1/2 study of pinometostat with standard chemotherapy in newly diagnosed acute myeloi…
-
CLINICAL_TRIALS trial_result · 2024-06-11Clinical Trial Update: RN-Led Palliative and Supportive Care Intervention [NA]
This clinical trial update notes that a nurse-led palliative and supportive care intervention for acute myeloid leukemia has completed, with…
-
CLINICAL_TRIALS trial_result · 2024-06-06Clinical Trial Update: Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia [Phase 1, Phase 2]
Phase I/II evaluation of S64315 in combination with azacitidine for acute myeloid leukemia has completed, with results posted on 2024-06-06.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-06-04Clinical Trial Update: Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients [Phase 2]
Phase 2 efficacy trial update for oral sapacitabine in elderly patients with acute myeloid leukemia; results were posted on 2024-06-04.
-
CLINICAL_TRIALS research · 2024-06-04Clinical Trial Update: CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant [Phase 1, Phase 2]
This clinical trial update examines using CD34+ malignant stem cell selection for patients receiving allogeneic stem cell transplants in Pha…
-
CLINICAL_TRIALS trial_result · 2024-06-04Clinical Trial Update: Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia [Phase 1]
Phase 1 study of pevonedistat in combination with azacitidine (or decitabine) and venetoclax for acute myeloid leukemia has been terminated.
-
CLINICAL_TRIALS research · 2024-06-04Clinical Trial Update: A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation [Phase 1]
A Phase 1 trial update evaluating the safety and efficacy of NCR300 to prevent recurrence of acute myeloid leukemia after transplantation; t…
-
CLINICAL_TRIALS trial_result · 2024-06-03Clinical Trial Update: A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420. [Phase 1]
An early-phase dose-escalation and expansion trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7283420…
-
CLINICAL_TRIALS trial_result · 2024-05-31Clinical Trial Update: A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia [Phase 1]
A Phase 1 safety and efficacy study of CC-90009 in acute myeloid leukemia has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-05-30Clinical Trial Update: Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia [Phase 3]
Phase 3 trial evaluating daunorubicin hydrochloride, cytarabine, and oblimersen sodium in previously untreated acute myeloid leukemia has co…
-
CLINICAL_TRIALS research · 2024-05-30Clinical Trial Update: Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML [Phase 2]
A Phase 2 clinical trial is evaluating a combination of mitoxantrone hydrochloride liposome injection, cytarabine, and venetoclax for relaps…
-
CLINICAL_TRIALS research · 2024-05-29Clinical Trial Update: Dynamics of Resistance Emergence to Azacitidine-based Therapies in Acute Myeloid Leukemia
This clinical trial investigates how resistance to azacitidine-based therapies emerges in acute myeloid leukemia and is currently recruiting…
-
CLINICAL_TRIALS research · 2024-05-29Clinical Trial Update: Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial is evaluating sulfasalazine added to intensive chemotherapy as first-line treatment for elderly patients wi…
-
CLINICAL_TRIALS trial_result · 2024-05-29Clinical Trial Update: Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure [Phase 2]
This Phase 2 trial is evaluating azacitidine or decitabine in combination with venetoclax for patients with Acute Myeloid Leukemia who previ…
-
CLINICAL_TRIALS research · 2024-05-29Clinical Trial Update: Single-cell Dynamic Profiling in Adults With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy. A THEMA Study"
The THEMA study is evaluating single-cell dynamic profiling in adults with newly diagnosed acute myeloid leukemia treated with intensive che…
-
CLINICAL_TRIALS research · 2024-05-29Clinical Trial Update: The Patient Cohort of the National Center for Precision Medicine in Leukemia
This clinical trial update describes the patient cohort for the National Center for Precision Medicine in Leukemia and notes that patient re…
-
CLINICAL_TRIALS trial_result · 2024-05-28Clinical Trial Update: Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486 [Phase 2]
A Phase 2 trial completed evaluating in vivo azacitidine incorporation in mononuclear cells after Vidaza or CC-486 treatment in patients wit…
-
CLINICAL_TRIALS trial_result · 2024-05-28Clinical Trial Update: Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory
A completed real-world study evaluating the use of azacitidine in combination with venetoclax for frontline and relapse/refractory acute mye…
-
CLINICAL_TRIALS research · 2024-05-28Clinical Trial Update: A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML) [Phase 2]
Phase 2 trial evaluating two schedules of entinostat (MS275) in combination with azacitidine (5-AC) in elderly patients with acute myeloid l…
-
EMA approval · 2024-05-24EMA Authorised: Vyxeos liposomal (previously Vyxeos) (daunorubicin hydrochloride;cytarabine) — Jazz Pharmaceuticals Ireland Limited
The European Medicines Agency authorised Vyxeos liposomal (daunorubicin hydrochloride and cytarabine) for acute myeloid leukemia, with orpha…
-
CLINICAL_TRIALS trial_result · 2024-05-23Clinical Trial Update: CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease [Phase 2]
Phase 2 trial comparing CPX-351 to immediate stem cell transplantation for high-grade myeloid cancers with measurable residual disease was t…
-
CLINICAL_TRIALS withdrawal · 2024-05-23Clinical Trial Update: Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With AML
The clinical trial NCT05309018 evaluating the integration of an advanced practice nurse in the complex care pathway for patients with acute …
-
CLINICAL_TRIALS trial_result · 2024-05-22Clinical Trial Update: Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse [Phase 2]
Phase 2 trial evaluating maintenance low-dose azacitidine after T cell–depleted allogeneic stem cell transplantation in high-risk myelodyspl…